ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Inosine-Triphosphate-Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectiveMethotrexate (MTX) is the first-line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients do not respond to it. Low inosine triphosphate pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated the role and underlying mechanisms of ITPA in vitro.
methodsITPA enzymatic activity was measured by high-performance liquid chromatography with ultraviolet detection in erythrocyte lysates from patients with JIA (enrolled in Trieste, Italy; Florence, Italy; and Kansas City, Missouri) receiving weekly MTX (10-15 mg/m
resultsA total of 195 patients with JIA (mean age: 8 years, range: 0-22 years, 74% female participants) were enrolled. Patients reaching remission (48%) had higher ITPA activity than nonresponders during therapy and at treatment onset (meta-analysis: P = 0.0004 and P = 0.007, respectively). Predictive cutoffs for overall and onset measurements were identified: 181.9 and 177.8 nmol of inosine monophosphate per hour. None of the patients with variant ITPA rs1127354 achieved remission (Fisher's exact test P = 0.0063); however, 48% of wild-type patients failed to respond. ITPA-overexpressing cells showed elevated MTX sensitivity, cAMP levels, PKA-Cα expression, and hypoxanthine (all P < 0.05, two-way analysis of variance).
conclusionITPA activity is a promising predictive biomarker for MTX response in JIA, outperforming ITPA rs1127354 genotyping. Its predictive value is evident at treatment initiation, supporting its use for personalized treatment. Mechanistically, higher enzyme activity may enhance MTX efficacy through the adenosine/inosine-ADORA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.